|
|||
Clinical data | |||
---|---|---|---|
Trade names | Sonata, Starnoc, Andante | ||
AHFS/Drugs.com | Monograph | ||
MedlinePlus | a601251 | ||
Pregnancy category |
|
||
Routes of administration |
Oral (medical), intranasal (recreational) | ||
ATC code | N05CF03 (WHO) | ||
Legal status | |||
Legal status |
|
||
Pharmacokinetic data | |||
Bioavailability | 30% (oral) | ||
Metabolism | Hepatic | ||
Biological half-life | 1–1.5 h | ||
Excretion | Renal | ||
Identifiers | |||
|
|||
CAS Number | 151319-34-5 | ||
PubChem (CID) | 5719 | ||
IUPHAR/BPS | 4345 | ||
DrugBank | DB00962 | ||
ChemSpider | 5517 | ||
UNII | S62U433RMH | ||
KEGG | D00530 | ||
ChEBI | CHEBI:10102 | ||
ChEMBL | CHEMBL1521 | ||
ECHA InfoCard | 100.126.674 | ||
Chemical and physical data | |||
Formula | C17H15N5O | ||
Molar mass | 305.34 g/mol | ||
3D model (Jmol) | Interactive image | ||
|
|||
|
|||
Zaleplon (marketed under the brand names Sonata, Starnoc, and Andante) is a sedative-hypnotic, almost entirely used for the management/treatment of insomnia. It is a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class.
Sonata (US) is manufactured by King Pharmaceuticals of Bristol, TN. Gedeon Richter Plc. manufactures zaleplon under the brand name Andante (RU). Starnoc has been discontinued in Canada but can be manufactured if a prescription is brought to a compounding pharmacy. It is prescribed rarely in the United Kingdom, with zopiclone being the preferred Z-drug by the National Health Service (NHS).
Zaleplon is slightly effective in the management/treatment of insomnia, primarily characterized by difficulty falling asleep. Due to its ultrashort elimination half-life, zaleplon may not be effective in reducing premature awakenings.
It may result in an impaired ability to drive the next day, though it has proven promising when compared to other sedative/hypnotics and next-day residual sedation. It may have advantages over benzodiazepines with fewer adverse effects.
Neither zaleplon, nor any nonbenzodiazepine hypnotic class medication should be combined with alcohol, as both modulate GABAA receptor sites, and in a synergistic manner increase the chances of fatal respiratory depression and asphyxiation from vomiting.